Silver Book Fact

Cost-effectiveness of TAVR in sSAS patients

Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY gained and $43,114 per life-year (LY) gained.

Reynolds M, Lei Y, Wang K, Chinnakondepalli K, et al. Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. JACC. 2016; 67(1): 29-38. http://www.onlinejacc.org/content/67/1/29

Reference

Title
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement
Publication
JACC
Publication Date
2016
Authors
Reynolds M, Lei Y, Wang K, Chinnakondepalli K, et al.
Volume & Issue
Volume 67, Issue 1
Pages
29-38
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states
     
  • TAVR Procedures 2011 – 2015
    From approval in 2011 through 2015, >54,000 transcatheter aortic valve replacements (TAVRs) were performed in 418 centers in 48 states.  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Surgical Aortic Valve Replacements in 2010
    In 2010, ~67,500 surgical aortic valve replacements (SAVR) were performed in the U.S.  
  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.